Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.52 |
| ▸ | OGA | O60502 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908731 | 0.85 | HRH3 (0.48) | USP30HRH3ALDH1A1LMNAMAPT | |
| SCHEMBL14018303 | 0.84 | HRH3 (0.56) | USP30HRH3P2RY12OGAKDM4E | |
| SCHEMBL6140015 | 0.81 | CKS1B (0.56) | USP30HRH3P2RY12OGAMAPT | |
| SCHEMBL9210857 | 0.79 | P2RY12 (0.65) | HRH3P2RY12OGAKDM4EALDH1A1 | |
| SCHEMBL6945090 | 0.79 | HRH3 (0.59) | USP30HRH3P2RY12OGAKDM4E | |
| SCHEMBL591858 | 0.78 | HRH3 (0.61) | USP30HRH3P2RY12OGAKDM4E | |
| SCHEMBL590388 | 0.78 | HRH3 (0.52) | USP30HRH3P2RY12OGAKDM4E | |
| SCHEMBL13449703 | 0.77 | HRH3 (0.47) | USP30HRH3ALDH1A1LMNAMAPT | |
| SCHEMBL2820792 | 0.77 | P2RY12 (0.64) | HRH3P2RY12OGAKDM4EALDH1A1 | |
| SCHEMBL590676 | 0.76 | HRH3 (0.59) | USP30HRH3P2RY12OGAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | USP30 3834/4885HRH3 186/4885P2RY12 135/4885 |
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | USP30 4624/4885HRH3 628/4885P2RY12 154/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | USP30 3841/4885HRH3 778/4885P2RY12 1929/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | USP30 4498/4885HRH3 318/4885P2RY12 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.